These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
369 related items for PubMed ID: 12730681
1. Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis. He Q, Montalbano J, Corcoran C, Jin W, Huang Y, Sheikh MS. Oncogene; 2003 May 01; 22(17):2674-9. PubMed ID: 12730681 [Abstract] [Full Text] [Related]
2. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. He Q, Lee DI, Rong R, Yu M, Luo X, Klein M, El-Deiry WS, Huang Y, Hussain A, Sheikh MS. Oncogene; 2002 Apr 18; 21(17):2623-33. PubMed ID: 11965535 [Abstract] [Full Text] [Related]
3. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. He Q, Luo X, Huang Y, Sheikh MS. Oncogene; 2002 Sep 05; 21(39):6032-40. PubMed ID: 12203115 [Abstract] [Full Text] [Related]
4. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, Bryant JL, Srivastava RK. Cancer Res; 2003 Apr 01; 63(7):1712-21. PubMed ID: 12670926 [Abstract] [Full Text] [Related]
5. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R, Bedi A. Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014 [Abstract] [Full Text] [Related]
6. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Suliman A, Lam A, Datta R, Srivastava RK. Oncogene; 2001 Apr 19; 20(17):2122-33. PubMed ID: 11360196 [Abstract] [Full Text] [Related]
7. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. He Q, Huang Y, Sheikh MS. Oncogene; 2004 Apr 01; 23(14):2554-8. PubMed ID: 14691451 [Abstract] [Full Text] [Related]
8. Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. Yamaguchi H, Bhalla K, Wang HG. Cancer Res; 2003 Apr 01; 63(7):1483-9. PubMed ID: 12670894 [Abstract] [Full Text] [Related]
9. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Sun SY, Yue P, Hong WK, Lotan R. Cancer Res; 2000 Dec 15; 60(24):7149-55. PubMed ID: 11156424 [Abstract] [Full Text] [Related]
10. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Izeradjene K, Douglas L, Tillman DM, Delaney AB, Houghton JA. Cancer Res; 2005 Aug 15; 65(16):7436-45. PubMed ID: 16103097 [Abstract] [Full Text] [Related]
11. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Deng Y, Lin Y, Wu X. Genes Dev; 2002 Jan 01; 16(1):33-45. PubMed ID: 11782443 [Abstract] [Full Text] [Related]
12. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis. Kim JY, Kim YH, Chang I, Kim S, Pak YK, Oh BH, Yagita H, Jung YK, Oh YJ, Lee MS. Oncogene; 2002 May 09; 21(20):3139-48. PubMed ID: 12082629 [Abstract] [Full Text] [Related]
13. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. Ruiz-Ruiz C, López-Rivas A. Biochem J; 2002 Aug 01; 365(Pt 3):825-32. PubMed ID: 11936954 [Abstract] [Full Text] [Related]
14. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Hao JH, Yu M, Liu FT, Newland AC, Jia L. Cancer Res; 2004 May 15; 64(10):3607-16. PubMed ID: 15150119 [Abstract] [Full Text] [Related]
15. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS. Oncogene; 2003 Aug 07; 22(32):4953-63. PubMed ID: 12902978 [Abstract] [Full Text] [Related]
16. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK. Int J Mol Med; 2005 Dec 07; 16(6):1125-38. PubMed ID: 16273296 [Abstract] [Full Text] [Related]
17. Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking Bax translocation. Kim M, Park SY, Pai HS, Kim TH, Billiar TR, Seol DW. Cancer Res; 2004 Jun 15; 64(12):4078-81. PubMed ID: 15205314 [Abstract] [Full Text] [Related]
18. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K, Douglas L, Delaney A, Houghton JA. Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455 [Abstract] [Full Text] [Related]
19. Trail-induced apoptosis in Type I leukemic cells is not enhanced by overexpression of bax. Jia L, Patwari Y, Kelsey SM, Newland AC. Biochem Biophys Res Commun; 2001 May 25; 283(5):1037-45. PubMed ID: 11355877 [Abstract] [Full Text] [Related]
20. Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-x(L) in a strictly caspase-3-dependent manner in human carcinoma cells. Hasenjäger A, Gillissen B, Müller A, Normand G, Hemmati PG, Schuler M, Dörken B, Daniel PT. Oncogene; 2004 Jun 03; 23(26):4523-35. PubMed ID: 15064710 [Abstract] [Full Text] [Related] Page: [Next] [New Search]